Ketamine Plus Lithium as a Novel Pharmacotherapeutic Strategy in Treatment Resistant Depression

ID Number 13-0365

Principal Investigator(s)
James Murrough

Department(s) or Division(s)


The purpose of this study is to test the antidepressant effect of ketamine when given repeatedly over a period of 1 week, as well as the use of Lithium as a relapse-prevention strategy for patients with treatment-resistant depression (TRD) who respond to an initial series of ketamine infusions. Ketamine is a Food and Drug Administration approved anesthetic (a drug used to produce loss of consciousness before and during surgery). Ketamine is not approved for the treatment of major depressive disorder and is considered experimental in this study.

One may qualify to take part in this research study if s/he has been diagnosed with major depressive disorder (MDD) and has not responded to past treatments. Participation in this study is expected to last at least 1 week. Eligible participants will receive treatment at no cost and compensation for their time.

Contact Information
Jaclyn Schwartz
(212) 241-3116

Recruiting Patients: Yes